Get the Stockscreener App
148.22
0.65%
0.95
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $148.22, with a volume of 3.08M.
It is up +0.65% in the last 24 hours and up +13.62% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$147.27
Open:
$147.86
24h Volume:
3.08M
Relative Volume:
1.24
Market Cap:
$35.69B
Revenue:
$222.29B
Net Income/Loss:
$1.56B
P/E Ratio:
23.12
EPS:
6.41
Net Cash Flow:
$2.44B
1W Performance:
-0.88%
1M Performance:
+13.62%
6M Performance:
+22.94%
1Y Performance:
+51.15%
1-Day Range:
$147.18
$149.74
1-Week Range:
$146.63
$154.07
52-Week Range:
$93.17
$154.07
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
148.22 | 35.69B | 222.29B | 1.56B | 2.44B | 6.41 |
|
MCK
Mckesson Corporation
|
693.46 | 88.78B | 344.58B | 2.83B | 1.63B | 21.84 |
|
COR
Cencora Inc
|
283.00 | 56.59B | 310.23B | 1.69B | 3.58B | 8.62 |
|
HSIC
Henry Schein Inc
|
68.64 | 7.95B | 12.50B | 314.00M | 421.00M | 2.44 |
|
OMI
Owens Minor Inc
|
7.01 | 580.18M | 10.42B | -38.77M | 323.54M | -0.51 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
Cardinal Health's (NYSE:CAH) Shareholders Will Receive A Bigger Dividend Than Last Year - simplywall.st
Cardinal Health (NYSE:CAH) Has Announced That It Will Be Increasing Its Dividend To $0.5107 - Yahoo Finance
Cardinal Health, Inc. (CAH): Among Billionaire Mason Hawkins’ Mid-Cap Stocks with Huge Upside Potential - Insider Monkey
-Charles River agrees with Elliott to add new directors, review business - marketscreener.com
Charles River to add new directors, review business in agreement with Elliott - marketscreener.com
Cardinal Health releases new report on the cell and gene therapy industry | CAH Stock News - GuruFocus
Cardinal Health releases new report on the cell and gene therapy industry - Stock Titan
Cardinal Health (NYSE:CAH) Announces Dividend Increase to US$1 Per Share - simplywall.st
Cardinal Health Board of Directors Approves Quarterly Dividend | - GuruFocus
Cardinal Health (CAH) Boosts Quarterly Dividend and Revises Earnings Guidance - GuruFocus
Cardinal Health Raises Dividend by About 1% - MarketWatch
Cardinal Health raises quarterly dividend to $0.5107 By Investing.com - Investing.com Canada
Cardinal Health Board of Directors Approves Quarterly Dividend - GuruFocus
Cardinal Health Increases Quarterly Dividend to $0.5107 a Share From $0.5056, Payable July 15 to Investors of Record July 1 - marketscreener.com
Cardinal Health Board of Directors Approves Quarterly Dividend | CAH Stock News - GuruFocus
Cardinal Health (CAH) Stock Target Price Increased by Morgan Stanley | CAH Stock News - GuruFocus
Argus Elevates Price Target for Cardinal Health (CAH) Amid Strat - GuruFocus
Are Investors Undervaluing Cardinal Health (CAH) Right Now? - Yahoo Finance
Cardinal Health (CAH) Price Target Increased by Morgan Stanley | - GuruFocus
Argus Adjusts Price Target on Cardinal Health to $162 From $148 - marketscreener.com
Cardinal Health’s Promising Growth Under New Leadership Justifies Buy Rating - TipRanks
Cardinal Health, Northrop Grumman Among 7 Companies To Announce Dividend Increases In First Half Of May - Seeking Alpha
Cardinal Health Third Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Cardinal Health (CAH): Analyst Raises Price Target Amid Strong P - GuruFocus
Cardinal Health (CAH): Analyst Raises Price Target Amid Strong Performance | CAH Stock News - GuruFocus
Cardinal Health cuts employees to offset up to $300M tariff charge - MedTech Dive
Cardinal Health CEO Jason Hollar on rising profits, record stock price - The Business Journals
Cardinal Health reports Q3 results, raises 2025 outlook - Drug Store News
UBS Elevates Price Target for Cardinal Health (CAH) to $170 | CA - GuruFocus
Cardinal Health (CAH) Price Target Raised by Baird Analyst | CAH Stock News - GuruFocus
UBS Elevates Price Target for Cardinal Health (CAH) to $170 | CAH Stock News - GuruFocus
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term - Yahoo Finance
Cardinal Health (CAH) Price Target Increased by Baird Analyst | - GuruFocus
Cardinal Health, Inc. (NYSE:CAH) Q3 2025 Earnings Call Transcript - MSN
Cardinal Health (CAH) Price Target Increased by Baird Analyst | CAH Stock News - GuruFocus
Cardinal Health Reaches Analyst Target Price - Nasdaq
Medtech companies try to head off price increases after tariffs - Modern Healthcare
Decoding Cardinal Health Inc (CAH): A Strategic SWOT Insight - GuruFocus
Cardinal Health Inc (CAH) Q3 2025 Earnings Call Highlights: Strong Earnings Growth and Raised ... - Yahoo Finance
Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks - AOL.com
Cardinal Health Inc (CAH) Q3 2025 Earnings Call Highlights: Strong Earnings Growth and Raised Guidance - GuruFocus
Cardinal Health raises FY 2025 EPS guidance to $8.05-$8.15 amid strong pharma growth and acquisitions - MSN
Cardinal Health (CAH) Boosts 2025 Outlook Following Strong Q3 - GuruFocus
Cardinal Health’s Earnings Call Highlights Growth and Challenges - TipRanks
Citi Increases Price Target for Cardinal Health (CAH) After Robu - GuruFocus
Citi Increases Price Target for Cardinal Health (CAH) After Robust Q3 Performance | CAH Stock News - GuruFocus
Cardinal Health Reports Third Quarter Fiscal Year 2025 Results a - GuruFocus
Facing up to $300M in tariff costs, Cardinal Health lays off employees - MassDevice
Cardinal Health Earnings: Resilient Demand, Strategic Acquisitions Help Slightly Exceed Expectations - Morningstar
Cardinal Health won't see real tariff impacts until FY26 – here's how it's prepared - The Business Journals
Strong Prescription Trend, Strategic Acquisitions, and Cost Control Fuel Cardinal's Momentum - Morningstar
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):